Yuansheng Hu

Sinovac Biotech — China

Medicine · Health Sciences

15h-index2.6kcitations44works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(10), Viral gastroenteritis research and epidemiology(9), Hepatitis B Virus Studies(6), Vaccine Coverage and Hesitancy(6), Viral Infections and Immunology Research(6)

Publications44 total

Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
Expert Review of Vaccines·2024Open Access
Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years
Vaccines·2023· 6 citedOpen Access
Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction
Human Vaccines & Immunotherapeutics·2023· 7 citedOpen Access
Safety and Effectiveness of SA58 Nasal Spray against SARS-CoV-2 family transmission: an exploratory single-arm trial
2023Open Access
Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
Human Vaccines & Immunotherapeutics·2022· 6 citedOpen Access
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Nature Communications·2022· 11 citedOpen Access
Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years
Vaccines·2022· 3 citedOpen Access
Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial
SSRN Electronic Journal·2022Open Access
Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis
Expert Review of Vaccines·2021· 16 cited
Translating daily COVID-19 screening into a simple glucose test: a proof of concept study
Chemical Science·2021· 62 citedOpen Access
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
The Lancet Infectious Diseases·2020· 1.5k citedOpen Access
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
2020· 95 citedOpen Access
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China
Human Vaccines & Immunotherapeutics·2020· 17 citedOpen Access
Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction
Human Vaccines & Immunotherapeutics·2020· 10 citedOpen Access
A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers
Chemical Science·2020· 105 citedOpen Access
Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains
Human Vaccines & Immunotherapeutics·2019· 15 citedOpen Access
Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1-3 years old children: a double-blind, randomized phase III trial
Human Vaccines & Immunotherapeutics·2018· 6 citedOpen Access
Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial
Vaccine·2018· 30 cited
A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly
Human Vaccines & Immunotherapeutics·2018· 15 citedOpen Access
A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months
Expert Review of Vaccines·2018· 14 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Fengcai Zhu(9), Kai Chu(7), Yuemei Hu(7), Jielai Xia(6), Changgui Li(5), Jingxin Li(5), Gang Zeng(5), Ji-Long Shen(5), Hongxing Pan(4), Weidong Yin(4), Yufei Song(4), Gang Zeng(3), Yaling Hu(3), Weixiao Han(3), Li-Fei Song(3), Miao Xu(3), Lili Huang(3), Shengli Xia(3), Hengming Zhang(3), Qiang Gao(3)